Collagenase clostridium histolyticum in patients with Dupuytren’s contracture: results from POINT X, an open-label study of clinical and patient-reported outcomes

In POINT X, a study designed to reflect clinical practice and patient treatment choices, 254 European patients received open-label collagenase for Dupuytren’s contracture. The most severely affected joint was treated first in 74% of patients. In total, 52%, 41%, 7%, and 1% of patients selected the l...

Descripción completa

Detalles Bibliográficos
Autores principales: Warwick, D., Arner, M., Pajardi, G., Reichert, B., Szabo, Z., Masmejean, E. H., Fores, J., Chapman, D. S., Gerber, R. A., Huard, F., Seghouani, A., Szczypa, P. P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2015
Materias:
Full Length Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4361452/
https://www.ncbi.nlm.nih.gov/pubmed/24470559
http://dx.doi.org/10.1177/1753193413519926

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4361452/
https://www.ncbi.nlm.nih.gov/pubmed/24470559
http://dx.doi.org/10.1177/1753193413519926

Ejemplares similares